SAG
RMD icon

SageView Advisory Group’s ResMed RMD Stock Holding History

SageView Advisory Group’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-163
Closed -$39.3K – 2034
2025
Q4 		$39.3K Buy
+163
New +$41.7K ﹤0.01% 1178

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

SageView Advisory Group's RMD Position: Q1 2026 in Review

SageView Advisory Group sold out of ResMed (RMD) in Q1 2026, closing a stake of 163 shares — an estimated $39.3K sold.

SageView Advisory Group first reported a position in RMD in Q4 2025 and held it in 1 quarter. The position peaked at $39.3K in Q4 2025. 945 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • SageView Advisory Group reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 163 ResMed shares in Q1 2026, an estimated $39.3K.
  • SageView Advisory Group first reported a position in ResMed in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's ResMed position peaked at $39.3K in Q4 2025.
  • 945 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.